Investigating how specific proteins regulate signaling pathways involved in cancer and autoimmune diseases
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling
This study is looking at a protein called ADAM17 to see how it works with other proteins to help us understand and find new ways to treat cancer and autoimmune diseases, which could lead to better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hospital for Special Surgery NIH-funded |
| Lab location | 1 site (New York, UNITED STATES) |
| Project ID | NIH-10755722 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of ADAM17, a protein that helps activate important signaling molecules involved in cancer and autoimmune diseases. By studying how ADAM17 is regulated by other proteins, particularly iRhoms, the research aims to uncover new therapeutic targets for treating conditions where these signaling pathways are disrupted. The approach includes genetic and biochemical analyses in mouse models to explore the mechanisms of ADAM17 activation and its impact on immune responses. Patients may benefit from insights gained that could lead to novel treatments for their conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases or cancers that involve dysregulation of the EGFR and TNFalpha signaling pathways.
Not a fit: Patients with conditions unrelated to EGFR or TNFalpha signaling may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for patients suffering from cancer and autoimmune diseases by targeting the mechanisms that regulate critical signaling pathways.
How similar studies have performed: Previous research has shown that targeting similar pathways has led to successful treatments in other contexts, indicating potential for success in this area as well.
Where this research is happening
New York, UNITED STATES
- Hospital for Special Surgery — New York, United States (Active)
Researchers
- Principal investigator: Blobel, Carl Peter — Hospital for Special Surgery
- Study coordinator: Blobel, Carl Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.